AtaGenix Laboratories

Home - About Us - Updates Center - Industry News

Global Antibody Discovery Market to Soar from USD 1.9B in 2024 to USD 3.3B by 2030

Release time: 2025-09-02   View volume: 21

Recent market analyses estimate the antibody discovery market at USD 1.9 billion (2024) with growth to USD 3.3 billion by 2030—a compound annual growth rate (CAGR) of about 9.8%. Momentum is driven by strong pipelines in monoclonal antibodies, rapid uptake of bispecifics, and accelerated investment in antibody–drug conjugates (ADCs).

Market Size (2024)
$1.9B
Forecast (2030)
$3.3B
CAGR (2024–2030)
~9.8%
Growth

What’s Driving the Growth?

1) Diversified Modalities
  • mAbs: Continued clinical success and lifecycle management for established targets.
  • Bispecifics: Expanding into oncology and autoimmune indications with novel pairings (e.g., CD3 x tumor antigens).
  • ADCs: Better linkers/payloads and target validation reduce attrition; more programs move to pivotal stages.
2) Faster, Smarter Discovery
  • Single B-cell platforms and naïve/immune libraries shorten timelines and improve epitope coverage.
  • AI/ML-assisted design speeds affinity maturation, developability screening, and liability prediction.
  • Stable cell line and process intensification de-risk scale-up into preclinical/clinical supply.

Market Snapshots

By Modality
Segment Trend
Monoclonal Antibodies (mAbs) Stable growth; new targets & next-gen formats sustain demand
Bispecific Antibodies Fastest growth; oncology & immunology pipelines expanding
ADCs Strong momentum; improved linkers/payloads & targeted indications
By Discovery Method
Approach Notes
Single B-cell Rapid hit-to-lead; native pairing preserves function
Phage/Yeast Display Large library diversity; efficient panning & optimization
Hybridoma Reliable for animal immunization routes & reagent antibodies
In-silico/AI Design/triage for affinity, specificity, and developability
By Region
Region Outlook
North America Largest share; robust venture & clinical activity
Europe Strong academia–industry networks; CDMO capacity expanding
Asia-Pacific Fastest growth; investment in discovery platforms and ADC pipelines

AtaGenix Insight

As the antibody discovery market expands, AtaGenix stands ready to accelerate customer programs across discovery, screening, and engineering—offering efficient, cost-effective platforms tailored to next-generation biologics. Our integrated capabilities include:
  • Single B-cell discovery (mouse, rabbit, human samples) and high-throughput sequencing
  • Naïve/immune library construction, phage display panning, and epitope binning
  • Humanization, affinity maturation, developability assessment, and stability engineering
  • Recombinant protein expression (E. coli / Yeast / Mammalian / Insect) and purification
  • Stable cell line development and upstream process optimization
Talk to our scientists to map an accelerated path from hit to IND-enabling studies.

Sources

Note: Figures (USD 1.9B in 2024; USD 3.3B in 2030; ~9.8% CAGR) reflect aggregated estimates from the sources above; methodologies may differ among publishers.

Messages